Markus Cornberg Selected Research

Hepatitis D

1/2022	HBcrAg Levels Are Associated With Virological Response to Treatment With Interferon in Patients With Hepatitis Delta.
1/2021	A transient early HBV-DNA increase during PEG-IFNα therapy of hepatitis D indicates loss of infected cells and is associated with HDV-RNA and HBsAg reduction.
1/2021	Residual low HDV viraemia is associated HDV RNA relapse after PEG-IFNa-based antiviral treatment of hepatitis delta: Results from the HIDIT-II study.
1/2019	Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial.
1/2017	Antiviral treatment and liver-related complications in hepatitis delta.
7/2014	Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta.
1/2014	Anti-HDV IgM as a marker of disease activity in hepatitis delta.
10/2011	Hepatitis D virus-specific cytokine responses in patients with chronic hepatitis delta before and during interferon alfa-treatment.
3/2009	Effect of peptide pools on effector functions of antigen-specific CD8+ T cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Markus Cornberg Research Topics

Disease

85	Infections 11/2022 - 02/2002
38	Chronic Hepatitis C 06/2022 - 02/2002
36	Hepatitis C 01/2022 - 07/2004
27	Fibrosis (Cirrhosis) 01/2022 - 01/2014
20	Hepatitis B 11/2022 - 04/2010
20	Chronic Hepatitis B 11/2022 - 04/2010
13	Liver Diseases (Liver Disease) 01/2022 - 01/2010
13	Virus Diseases (Viral Diseases) 01/2021 - 02/2002
12	Chronic Hepatitis (Chronic Active Hepatitis) 01/2020 - 01/2010
11	Hepatitis 01/2021 - 01/2010
10	Ascites 01/2022 - 01/2017
10	Hepatocellular Carcinoma (Hepatoma) 01/2021 - 05/2012
9	Hepatitis D 01/2022 - 03/2009
8	COVID-19 01/2022 - 06/2020
8	Liver Cirrhosis (Hepatic Cirrhosis) 01/2020 - 01/2010
7	Neoplasms (Cancer) 01/2021 - 01/2017
5	Coinfection 01/2022 - 01/2012
5	Disease Progression 01/2021 - 10/2008
5	Persistent Infection 01/2021 - 02/2006
4	Inflammation (Inflammations) 01/2022 - 01/2010
3	Cross Infection (Nosocomial Infection) 01/2022 - 01/2020
3	Non-alcoholic Fatty Liver Disease 01/2021 - 12/2016
2	Portal Hypertension 01/2022 - 01/2021
2	Peritonitis 01/2022 - 01/2018
2	Acute-On-Chronic Liver Failure 01/2022 - 01/2021
2	Acute Kidney Injury (Acute Renal Failure) 01/2022 - 01/2018
2	Convalescence 01/2022 - 01/2021
2	Lymphopenia (Lymphocytopenia) 12/2021 - 01/2021
2	Communicable Diseases (Infectious Diseases) 01/2021 - 01/2019
2	Viremia 01/2021 - 01/2010
2	Hemorrhage 01/2021 - 01/2017
2	End Stage Liver Disease 01/2021 - 12/2020
2	Hepatitis A (Hepatitis, Infectious) 08/2017 - 12/2006
2	HIV Infections (HIV Infection) 12/2012 - 11/2011
1	Mental Disorders (Mental Disorder) 01/2022
1	Myocarditis (Carditis) 01/2022

Drug/Important Bio-Agent (IBA)

46	Antiviral Agents (Antivirals)IBA 06/2022 - 12/2002
29	InterferonsIBA 01/2022 - 02/2002
27	RNA (Ribonucleic Acid)IBA 01/2022 - 12/2006
24	Hepatitis B Surface Antigens (HBsAg)FDA Link 11/2022 - 04/2010
20	Ribavirin (Virazole)FDA LinkGeneric 10/2019 - 02/2002
16	AntigensIBA 11/2022 - 06/2006
15	Interferon-alpha (Interferon Alfa)IBA 01/2022 - 02/2002
13	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 12/2009
12	Biomarkers (Surrogate Marker)IBA 11/2022 - 11/2011
12	Hepatitis B e AntigensIBA 11/2022 - 04/2010
12	CytokinesIBA 01/2022 - 10/2011
9	Peptides (Polypeptides)IBA 10/2019 - 09/2007
7	VaccinesIBA 01/2021 - 08/2015
7	BilirubinIBA 01/2020 - 08/2014
6	AntibodiesIBA 01/2022 - 01/2010
6	EpitopesIBA 10/2019 - 01/2007
5	Proteins (Proteins, Gene)FDA Link 01/2021 - 10/2004
5	Pharmaceutical PreparationsIBA 02/2020 - 07/2011
5	peginterferon alfa-2a (Pegasys)FDA Link 01/2020 - 10/2015
4	Immunoglobulin G (IgG)IBA 01/2022 - 01/2010
4	Alanine Transaminase (SGPT)IBA 01/2022 - 02/2016
4	SofosbuvirIBA 01/2020 - 05/2013
4	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2020 - 12/2005
3	glecaprevir and pibrentasvirIBA 01/2022 - 01/2020
3	Interleukin-10 (Interleukin 10)IBA 01/2021 - 10/2002
3	LigandsIBA 01/2021 - 05/2010
3	ChemokinesIBA 01/2021 - 12/2016
3	COVID-19 VaccinesIBA 01/2021 - 01/2021
3	InterleukinsIBA 01/2021 - 10/2011
3	AlbuminsIBA 01/2019 - 08/2014
3	Protease Inhibitors (Protease Inhibitor)IBA 07/2015 - 01/2013
3	N- (3- amino- 1- (cyclobutylmethyl)- 2,3- dioxopropyl)- 3- (2- ((((1,1- dimethylethyl)amino)carbonyl)amino)- 3,3- dimethyl- 1- oxobutyl)- 6,6- dimethyl- 3- azabicyclo(3.1.0)hexan- 2- carboxamideIBA 08/2014 - 02/2012
2	EnzymesIBA 01/2022 - 05/2016
2	gamma-Glutamyltransferase (gamma-Glutamyl Transpeptidase)IBA 01/2022 - 01/2020
2	Meropenem (Merrem)FDA LinkGeneric 01/2022 - 07/2021
2	Tenofovir (Viread)FDA Link 01/2022 - 01/2019
2	Blood Proteins (Serum Proteins)IBA 12/2021 - 12/2016
2	Interleukin-17 (Interleukin 17)IBA 01/2021 - 10/2019
2	Lymphotoxin-alpha (Lymphotoxin)IBA 01/2021 - 11/2009
2	Proton Pump InhibitorsIBA 08/2019 - 01/2018
2	Messenger RNA (mRNA)IBA 01/2019 - 10/2004
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 11/2016 - 05/2010
2	T-Lymphocyte Epitopes (Epitopes, T Lymphocyte)IBA 11/2015 - 01/2012
2	telaprevirIBA 08/2014 - 01/2013
2	Immunoglobulin M (IgM)IBA 01/2014 - 12/2006
2	peginterferon alfa-2b (Pegintron)FDA Link 06/2013 - 09/2011
2	Natural Killer Cell ReceptorsIBA 05/2012 - 11/2011
2	Interferon alpha-2 (Roferon-A)FDA Link 07/2004 - 12/2002
1	Neutralizing AntibodiesIBA 01/2022
1	sofosbuvir drug combination ledipasvirIBA 01/2022
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2022
1	2,6-dinitrotoluene (DNT)IBA 01/2022
1	Circular DNAIBA 01/2022

Therapy/Procedure

63	Therapeutics 11/2022 - 12/2002
15	Liver Transplantation 01/2022 - 10/2006
4	Transplantation 01/2021 - 01/2010
4	Immunotherapy 01/2020 - 05/2011
3	Transjugular Intrahepatic Portasystemic Shunt 01/2022 - 01/2021
3	Aftercare (After-Treatment) 01/2021 - 01/2018
3	Duration of Therapy 01/2020 - 10/2006
2	Surgical Portasystemic Shunt (Portosystemic Shunt) 01/2022 - 01/2020
2	Drug Therapy (Chemotherapy) 01/2022 - 01/2018
2	Investigational Therapies (Experimental Therapy) 01/2020 - 11/2019
1	Contraindications 01/2022